| NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer B Salomé, JP Sfakianos, D Ranti, J Daza, C Bieber, A Charap, C Hammer, ... Cancer Cell 40 (9), 1027-1043. e9, 2022 | 50 | 2022 |
| Epithelial plasticity can generate multi-lineage phenotypes in human and murine bladder cancers JP Sfakianos, J Daza, Y Hu, H Anastos, G Bryant, R Bareja, KK Badani, ... Nature communications 11 (1), 2540, 2020 | 43 | 2020 |
| Pathological downstaging as a novel endpoint for the development of neoadjuvant chemotherapy for upper tract urothelial carcinoma A Martini, J Daza, E Poltiyelova, Z Gul, JR Heard, BS Ferket, ... BJU international 124 (4), 665-671, 2019 | 42 | 2019 |
| Bacillus Calmette-Guerin (BCG): Its fight against pathogens and cancer JP Sfakianos, B Salome, J Daza, A Farkas, N Bhardwaj, A Horowitz Urologic Oncology: Seminars and Original Investigations 39 (2), 121-129, 2021 | 38 | 2021 |
| Neoadjuvant versus adjuvant chemotherapy for upper tract urothelial carcinoma A Martini, UG Falagario, N Waingankar, J Daza, PJ Treacy, A Necchi, ... Urologic Oncology: Seminars and Original Investigations 38 (8), 684. e9-684. e15, 2020 | 12 | 2020 |
| Role of the innate immune system in the development, progression, and therapeutic response of bladder cancer J Daza, A Charap, PN Wiklund, JP Sfakianos European Urology Focus 6 (4), 650-652, 2020 | 11 | 2020 |
| Survival of patients with muscle-invasive urothelial cancer of the bladder with residual disease at time of cystectomy: a comparative survival analysis of treatment modalities … JL Pfail, F Audenet, A Martini, N Tomer, I Paranjpe, J Daza, K Attalla, ... Bladder Cancer 6 (3), 265-276, 2020 | 9 | 2020 |
| Black race may be associated with worse overall survival in renal cell carcinoma patients H Anastos, A Martini, N Waingankar, DJ Paulucci, AT Beksac, J Daza, ... Urologic Oncology: Seminars and Original Investigations 38 (12), 938. e9-938 …, 2020 | 6 | 2020 |
| Do patients with Stage 3–5 chronic kidney disease benefit from ischaemia‐sparing techniques during partial nephrectomy? AT Beksac, KE Okhawere, DC Rosen, A Elbakry, BD Dayal, J Daza, ... BJU international 125 (3), 442-448, 2020 | 6 | 2020 |
| Identifying tumor-related risk factors for simultaneous adrenalectomy in patients with cT1-cT2 kidney cancer during robotic assisted laparoscopic radical nephrectomy. J Daza, AT Beksac, M Kannappan, J Chong, R Abaza, A Hemal, ... Minerva Urology and Nephrology 73 (1), 72-77, 2019 | 5 | 2019 |
| Urine supernatant reveals a signature that predicts survival in clear‐cell renal cell carcinoma J Daza, B Salomé, K Okhawere, O Bane, KN Meilika, TG Korn, J Qi, H Xe, ... BJU international 132 (1), 75-83, 2023 | 4 | 2023 |
| The role of RENAL score in predicting complications after robotic partial nephrectomy. J Daza, KE Okhawere, O Ige, A Elbakry, JP Sfakianos, R Abaza, ... Minerva Urology and Nephrology 74 (1), 57-62, 2021 | 4 | 2021 |
| Tumor-Infiltrating Myeloid Cells Confer De Novo Resistance to PD-L1 Blockade through EMT–Stromal and Tgfβ-Dependent Mechanisms H Yu, JP Sfakianos, L Wang, Y Hu, J Daza, MD Galsky, HS Sandhu, ... Molecular cancer therapeutics 21 (11), 1729-1741, 2022 | 2 | 2022 |
| Functional outcomes after robotic radical cystectomy with intracorporeal diversion: a systematic review J Daza, T Jones, M Raven, A Charap, JP Sfakianos, R Mehrazin, ... Bladder Cancer 6 (3), 329-342, 2020 | 2 | 2020 |
| Role of heat shock proteins in bladder cancer: potential biomarkers for treatment response and oncological prognosis J Daza, Z Gul, JP Sfakianos Translational Andrology and Urology 8 (Suppl 3), S240, 2019 | 2 | 2019 |
| Enfermedad de Von Gierke: nuevas tendencias en el manejo JA Daza Cárdenas Revista Med 20 (2), 60-64, 2012 | 2 | 2012 |
| Does testosterone replacement therapy increase the risk of conversion to treatment in patients with prostate cancer on active surveillance? J Daza, A Ahmad, U Shabir, Z Jing, M Shiekh, E Kauffman, KA Guru, ... Urologic Oncology: Seminars and Original Investigations 41 (10), 429. e1-429. e7, 2023 | 1 | 2023 |
| Development of a predictive model for recurrence-free survival in pTa low-grade bladder cancer J Daza, R Grauer, S Chen, E Lavallèe, S Razdan, L Dey, G Steineck, ... Urologic Oncology: Seminars and Original Investigations 41 (5), 256. e9-256. e15, 2023 | 1 | 2023 |
| NKG2A and HLA-E define a novel alternative immune checkpoint axis in bladder cancer B Salomé, JP Sfakianos, J Daza, A Charap, C Hammer, R Banchereau, ... bioRxiv, 2022.03. 04.482960, 2022 | 1 | 2022 |
| 621 NKG2A and HLA-E define a novel mechanism of resistance to immunotherapy with M. bovis BCG in non-muscle-invasive bladder cancer patients A Horowitz, J Daza, YA Wang, D Ranti, B Salome, E Merritt, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021 | 1 | 2021 |
Alberto MartiniMD Anderson Cancer CenterVerified email at mdanderson.org
